Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 2.93 Billion | USD 7.05 Billion | 9.2% | 2024 |
FrequentlyAsked Questions
Factor Xa is a serine protease-like trypsin that plays an important role in the cascade of blood coagulation. Apixaban mechanism works on Xa factor inhibiting which indirectly decreases thrombin-stimulated clot formation. Precisely, apixaban is an anticoagulant medicine utilized for treating and preventing blood clots & heart strokes in patients. In addition to this, Apixaban is recommended in patients with non-valvular atrial fibrillation to reduce the risk of stroke or systemic embolism.
The global apixaban market is expected to grow due to increasing prevalence of cardiovascular diseases, the growing geriatric population, Apixaban's favorable safety and efficacy profile compared to traditional anticoagulants, and the rising demand for novel oral anticoagulants (NOACs) due to their convenien.
According to a study, the global apixaban market size was worth around USD 2.93 Billion in 2024 and is expected to reach USD 7.05 Billion by 2034.
The global apixaban market is expected to grow at a CAGR of 9.2% during the forecast period.
North America is expected to dominate the apixaban market over the forecast period.
Leading players in the global apixaban market include F. Hoffmann-La Roche Ltd. (Switzerland), Mylan NV (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GSK plc (UK), Novartis AG (Switzerland), AstraZeneca (UK), Johnson & Johnson Private Limited (US), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Lilly (US), Amgen Inc. (US), Eisai Co., Ltd (Japan), Aspen Holdings (South Africa), Fresenius Kabi AG (Germany), Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. (China), OPOCRIN SPA (Italy), SARIA International GmbH (Germany), Hepalink Group (China)., Shenzhen Techdow Pharmaceutical Co., Ltd (China), Yino Pharma Limited (China), among others.
The report explores crucial aspects of the apixaban market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed